Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Idun Pharmaceuticals Inc.

Division of Conatus Pharmaceuticals Inc.

Latest From Idun Pharmaceuticals Inc.

Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.

Deals M & A

Conatus Acquires Idun's Assets

As it divests assets to restructure its research and development pipeline, Pfizer Inc. has found the best buyers are intimately familiar with what they're getting. In late July, the big pharma revealed it sold its Idun Pharmaceuticals Inc. subsidiary to Conatus Pharmaceuticals Inc., a startup founded by the same executives who led Idun prior to its nearly $300 million acquisition by Pfizer in 2005.

BioPharmaceutical Strategy

Hamade's Compass Leads to Aberdare

In the eyes of one West Coast device VC, Sami Hamade has the perfect resume to be a venture capitalist. He spent over a decade at Guidant creating or funding new start-up ventures, both internally and externally. He's sat on boards, demonstrated market savvy and established connections with all the right venture firms and laboratories in Silicon Valley. Now Hamade is prepared to do the job at Aberdare Ventures, a small but highly regarded venture firm based in San Francisco.

Medical Device Business Strategies

Pfizer's Analyst Day: And Now, For Its Next Trick

Pfizer was vague in describing to analysts just how it would reduce costs by $4 billion per year by 2008. The FDA's announcement that it had asked Pfizer to remove the Cox-2 inhibitor Bextra from the market just days later complicates matters for the pharmaceutical giant. In any case, those hoping for a significant headcount reduction among Pfizer sales reps were surely disappointed.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Conatus Pharmaceuticals Inc.
  • Senior Management
  • Steven J Mento, PhD, Pres. & CEO
    Charles Cashion, EVP, CFO
    Jennifer Giottonini, VP, Corp. Dev.
  • Contact Info
  • Idun Pharmaceuticals Inc.
    Phone: (858) 623-1330
    9380 Judicial Dr.
    San Diego, CA 92121